Detection of Hemostasis Abnormalities in Type 2 Diabetes Mellitus Using Thromboelastography
https://doi.org/10.15605/jafes.037.02.12
- Author:
Putu Moda Arsana
1
;
Novi Khila Firani
2
;
Siti Fatonah
2
;
Affa Kiysa Waafi
3
;
Adinda Dian Novitasari
3
Author Information
1. Endocrine, Diabetes, and Metabolism Division, Internal Medicine Department, Faculty of Medicine, Universitas Brawijaya, Indonesia
2. Clinical Pathology Department, Faculty of Medicine, Universitas Brawijaya, Indonesia
3. Internal Medicine Department, Faculty of Medicine, Universitas Brawijaya, Indonesia
- Publication Type:Journal Article
- MeSH:
Diabetes Mellitus;
Thrombelastography;
Hemostasis
- From:
Journal of the ASEAN Federation of Endocrine Societies
2022;37(2):42-48
- CountryPhilippines
- Language:English
-
Abstract:
Introduction:Type 2 DM (T2DM) is associated with inflammation and vascular dysfunction which impact hemostasis. Thromboelastography (TEG) as a hemostasis assessment method, is not routinely applied in T2DM.
Methodology:A cross-sectional study was conducted among T2DM patients attending the Endocrinology Clinic of Saiful Anwar Hospital, Indonesia. Glycemic profiles were determined using fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPPG), and glycosylated hemoglobin (HbA1c). Therapy for T2DM was classified into insulin and non-insulin regimens. The primary and secondary hemostasis profile were examined using TEG and was classified as hypo- hyper- and normo-coagulable states.
Result:A total of 57 T2DM patients were included. Kruskal-Wallis test did not reveal a significant association between glycemic profiles and groups of hemostasis. However, the median HbA1c was higher in the hypercoagulable group of primary hemostasis and fibrinolysis. The median FPG and 2hPPG were higher in the normo-coagulable group of secondary hemostasis. Logistic regression did not indicate a significant association between type of therapy for diabetes and hemostasis profile.
Conclusion:This study did not find significant associations between glycemic levels and type of DM therapy with hemostasis profiles using the TEG method in patients with T2DM.
- Full text:1291-Article Text-21591-1-10-20221125 (1).pdf
